News US lawmakers back 'right to try' legislation US lawmakers have approved new laws giving terminally ill patients the “right to try” unapproved drugs if there are no alternatives.
News Spark/Pfizer eye phase 3 trial of haemophilia B gene therapy Spark Therapeutics has already revolutionised treatment of a rare hereditary eye disease with a gene therapy, but could it be about to do the same with haemophilia B?
News Roche haemophilia data piles pressure on Shire Hemlibra threatens to take market share from Advate
Partner Content Partner Content OPEN Health invest in rare disease OPEN Health invest in rare disease
News Solomon quits as Akari CEO following credit card probe Biotech veteran quits after less than a year in charge
News Takeda to cut IT, marketing and sales jobs after Shire merge... Takeda aiming for $1.4bn savings per year
News Aspen, Bambusa close IPOs as Corxel takes SPAC route Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
